Goldman Sachs’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $190K | Buy |
+30,927
| New | +$220K | ﹤0.01% | 6099 |
|
|
2025
Q2 | – | Sell |
-15,775
| Closed | -$208K | – | 6373 |
|
|
2025
Q1 | $208K | Sell |
15,775
-11,750
| -43% | -$210K | ﹤0.01% | 5626 |
|
|
2024
Q4 | $493K | Buy |
27,525
+16,189
| +143% | +$328K | ﹤0.01% | 5257 |
|
|
2024
Q3 | $183K | Buy |
+11,336
| New | +$177K | ﹤0.01% | 5485 |
|
|
2024
Q2 | – | Sell |
-39,335
| Closed | -$23M | – | 5878 |
|
|
2024
Q1 | $23M | Sell |
39,335
-10,232
| -21% | -$217K | ﹤0.01% | 1720 |
|
|
2023
Q4 | $1.03M | Buy |
49,567
+4,958
| +11% | +$148K | ﹤0.01% | 4370 |
|
|
2023
Q3 | $1.42M | Sell |
44,609
-2,420
| -5% | -$80.8K | ﹤0.01% | 4019 |
|
|
2023
Q2 | $1.58M | Buy |
47,029
+34,172
| +266% | +$1.22M | ﹤0.01% | 4038 |
|
|
2023
Q1 | $536K | Buy |
12,857
+10,252
| +394% | +$482K | ﹤0.01% | 4780 |
|
|
2022
Q4 | $88.3K | Sell |
2,605
-2,396
| -48% | -$102K | ﹤0.01% | 5506 |
|
|
2022
Q3 | $246K | Sell |
5,001
-3,755
| -43% | -$206K | ﹤0.01% | 5389 |
|
|
2022
Q2 | $344K | Sell |
8,756
-29,886
| -77% | -$886K | ﹤0.01% | 5332 |
|
|
2022
Q1 | $1.43M | Sell |
38,642
-2,235
| -5% | -$140K | ﹤0.01% | 4540 |
|
|
2021
Q4 | $4M | Sell |
40,877
-2,334
| -5% | -$251K | ﹤0.01% | 3632 |
|
|
2021
Q3 | $5.39M | Sell |
43,211
-10,600
| -20% | -$1.28M | ﹤0.01% | 3295 |
|
|
2021
Q2 | $6.75M | Sell |
53,811
-17,060
| -24% | -$2.03M | ﹤0.01% | 3074 |
|
|
2021
Q1 | $9.62M | Buy |
70,871
+51,185
| +260% | +$6.35M | ﹤0.01% | 2598 |
|
|
2020
Q4 | $1.79M | Buy |
19,686
+13,135
| +201% | +$1.14M | ﹤0.01% | 3815 |
|
|
2020
Q3 | $487K | Buy |
6,551
+4,668
| +248% | +$358K | ﹤0.01% | 4497 |
|
|
2020
Q2 | $160K | Sell |
1,883
-1,294
| -41% | -$117K | ﹤0.01% | 4873 |
|
|
2020
Q1 | $230K | Buy |
3,177
+2,587
| +438% | +$250K | ﹤0.01% | 4645 |
|
|
2019
Q4 | $42K | Sell |
590
-235
| -28% | -$11.3K | ﹤0.01% | 5129 |
|
|
2019
Q3 | $43K | Buy |
825
+116
| +16% | +$6.16K | ﹤0.01% | 5062 |
|
|
2019
Q2 | $38K | Sell |
709
-24
| -3% | -$1.64K | ﹤0.01% | 5034 |
|
|
2019
Q1 | $52K | Sell |
733
-283
| -28% | -$17.9K | ﹤0.01% | 4999 |
|
|
2018
Q4 | $81K | Buy |
1,016
+202
| +25% | +$46.1K | ﹤0.01% | 5034 |
|
|
2018
Q3 | $380K | Buy |
814
+201
| +33% | +$80.8K | ﹤0.01% | 4571 |
|
|
2018
Q2 | $244K | Buy |
613
+243
| +66% | +$86.2K | ﹤0.01% | 4895 |
|
|
2018
Q1 | $113K | Sell |
370
-612
| -62% | -$174K | ﹤0.01% | 5237 |
|
|
2017
Q4 | $289K | Buy |
+982
| New | +$429K | ﹤0.01% | 5198 |
|
|
2017
Q2 | – | Sell |
-1,053
| Closed | -$452K | – | 6940 |
|
|
2017
Q1 | $452K | Buy |
1,053
+478
| +83% | +$201K | ﹤0.01% | 5125 |
|
|
2016
Q4 | $296K | Sell |
575
-1,234
| -68% | -$721K | ﹤0.01% | 5497 |
|
|
2016
Q3 | $773K | Buy |
1,809
+976
| +117% | +$381K | ﹤0.01% | 4643 |
|
|
2016
Q2 | $350K | Buy |
+833
| New | +$350K | ﹤0.01% | 5209 |
|
Other funds holding RNAC
VCM
6CM
EAM
Goldman Sachs's RNAC Position: Q1 2026 in Review
Goldman Sachs opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 30,927 shares worth $190K. The stake represents ﹤0.01% of the portfolio and ranks #6099 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in RNAC as recently as Q1 2025.
Goldman Sachs first reported a position in RNAC in Q2 2016 and has held it in 34 quarters since. The position peaked at $23M in Q1 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Goldman Sachs held 30,927 shares of Cartesian Therapeutics worth $190K as of Q1 2026.
- Cartesian Therapeutics was a new Goldman Sachs position in Q1 2026.
- Cartesian Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6099 holding.
- Goldman Sachs first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 34 quarters since.
- Goldman Sachs's Cartesian Therapeutics position peaked at $23M in Q1 2024.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.